|
|
|
|
||
AbbVie preps filings for lymphoma bispecific licensed from Genmab Pharma & Healthcare Monitor Worldwide AbbVie preps filings for lymphoma bispecific licensed from GenmabThe drugmaker has reported top-line results from the phase 1/2 EPCORE trial of epcoritamab as a third-line therapy for relapsed/refractory LBCL, revealing an overall response rate of 63% and a median duration of response of 12 months. The results are particularly notable because more than a third (39%) of the 157 patients enrolled into the study had previously been treated with CAR-Ts, potentially providing another line of treatment for the 60% to 70% of patients who dont achieve lasting remission with the cell therapies. Epcoritamab is a bispecific antibody which targets CD3 on white blood cells and CD20 on tumour cells, and is designed to encourage an immune response against the cancer. Analysts at Jefferies have previously said they think epcoritamab could become a $1.5 billion product at peak. It was one of Genmabs lead in-house development projects prior to the AbbVie partnership, which also includes two other named antibodies and a drug discovery collaboration, and the project the Danish biotech has held up as being key to its ambition to start selling its own products. Genmab and AbbVie share commercial rights to the drug in the US and Japan, with AbbVie having sole rights elsewhere in the world. Other companies are developing CD3xCD20 bispecifics as well, including Roches mosunetuzumab and CD20-TCB and Regenerons REGN5678, which are already in clinical trials, although AbbVie is thought to be closest to market. We aim to leverage AbbVies strong blood cancer expertise to further develop epcoritamab, alongside Genmab, for certain blood cancer patients who have limited treatment options, said Mohamed Zaki, AbbVies head of oncology development. The two companies are also running a phase 3 trial of the bispecific as a monotherapy in patients with relapsed/refractory diffuse LBCL. |
return to message board, top of board |